Abstract
Migraine is a recurrent throbbing or pulsing headache with moderate to severe pain intensity. The pain is often one side of the head with nausea and weakness symptoms. Around 12 percent of Americans, 9 percent of Asians experiences migraine and the prevalence is highest among South Koreans (22.3%). The outcome of chronic migraine treatment can be quite disheartening, causing patients to feel out of options who have tried multiple treatments with no results. Poor efficacy, tolerability and safety of migraine preventive therapy in clinical practice lead to poor compliance and failure of therapy. The mean change in number or frequency of headache is considered as the outcome measure of migraine prevention therapy. Upon comparing all migraine prevention therapy, the Fremanezumab, Eptinezumab, Galcanezumab and Erenumab were considered as the front runner in controlling the severity and frequency of migraine. Among these drugs, Erenumab was most effective in controlling the frequency of migraine episodes as it produces more than 50 percent reduction in the mean number of monthly migraine days (MMD) over week 9-week 12. In addition to drug therapy, adequate rest, balanced diet, yoga and meditation will help patients to get rid of migraine severity. A multi-dimensional approach is essential for better control over migraine symptoms.
Highlights
Migraine is an extremely usual, persistent, and normally geneticallyrelated neurovascular disorder which occurs at irregular intervals [1]
Migraine attacks comprise of severe headaches which accompany by a group of symptoms, lasting for four to seventy-two hours, for instance, nausea, vomiting, photo-and phonophobia [2]
ARISE [59] was a phase 3 study conducted over 3 mo, in which the monthly subcutaneous injections of 70 mg of erenumab vs placebo were studied in 577 episodic migraine (EM) patients, and the change in monthly migraine days (MMD) as primary outcome was assessed in month 3 of the treatment phase
Summary
Migraine is an extremely usual, persistent, and normally geneticallyrelated neurovascular disorder which occurs at irregular intervals [1]. In 2015, the study reported that migraine was considered one of the eight chronic diseases which influenced more than 10% of the global population [17] Gender wise, it had a greater impact on women compared to men, with prevalence of 17% and 6% respectively, resulting to a remarkable socioeconomic burden to the society. Migraine related to the people’s socioeconomic burden, with respect to both standard of living and lost efficacy [19] This is supported by previous studies, which indicated that about 9 out of 10 migraine patients are functionally affected during an attack, approximately half of them are gravely impaired and in need of bed rest. The summary of the efficacy and safety of newer drugs that recently approved for the treatment of migraine are compared and presented in table 1
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmacy and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
